Biomarker: M013-IgE Phoma betae

Overview

M013-IgE measures allergen-specific immunoglobulin E (IgE) antibodies directed against Phoma betae, an airborne mold. IgE bound to mast cells and basophils can trigger release of inflammatory mediators when it encounters the relevant allergen, contributing to immediate hypersensitivity reactions. A detectable or elevated result indicates sensitization and may support Phoma betae allergy, including allergic rhinitis, asthma, or other mold-related respiratory symptoms, but it does not by itself establish symptomatic clinical allergy. The test is clinically useful when interpreted with exposure history, symptoms, and other allergy evaluations to help identify relevant mold sensitization.

Clinical Use Cases

Evaluation of suspected Phoma betae allergy in patients with rhinitis, asthma, wheezing, or other symptoms associated with mold exposure.
Identification of Phoma betae as a possible allergen contributing to respiratory allergic disease.
Assessment of mold sensitization when skin testing is impractical, unavailable, or unsuitable.
Supporting evaluation of suspected hypersensitivity pneumonitis or other mold-associated respiratory disease when clinically indicated.
Characterization of sensitization patterns alongside other mold-specific IgE tests. Studies have reported frequent concurrent sensitization to Alternaria alternata, although cross-reactivity and multiple independent sensitizations may both contribute.
Supporting allergen identification before consideration of allergen-specific management, when the result is clinically relevant.

Specimen Types

Serum obtained from venous blood.
No established routine use of saliva, urine, or other non-blood specimens for this specific measurement.

Measurement Methods

Fluorescence enzyme immunoassay using an immobilized Phoma betae allergen, such as an ImmunoCAP-based assay.
Older research methods include radioallergosorbent testing, or RAST, for detecting mold-specific IgE.
Skin-prick testing is an alternative method for assessing sensitization, but it does not measure serum M013-specific IgE.

Test Preparation and Influencing Factors

Fasting is generally not required for serum-specific IgE testing.
Antihistamines generally do not affect serum-specific IgE measurements, although they can interfere with skin-prick testing.
Results should be interpreted with the patient’s symptoms, exposure history, age, season, and other allergen test results.
A positive result indicates sensitization and does not necessarily prove that exposure causes symptoms.
The measured IgE concentration does not reliably predict the severity of clinical reactions.
Cross-reactivity or sensitization to other molds may contribute to a positive result.
Markedly elevated total serum IgE may produce nonspecific binding and potentially false-positive specific-IgE results.
Testing after allergen immunotherapy may not reliably determine whether clinically relevant sensitivity remains and should be interpreted by an allergy specialist.
Collection, handling, and transport requirements depend on the performing laboratory. Serum is typically separated from blood cells and submitted in a suitable tube.